Skip to main content

Oliviero James F III's Form 4 filing

Checkpoint Therapeutics, Inc. (CKPT) · filed Apr 22, 2022

Accession no.
0001104659-22-049156
Filed
Apr 22, 2022
Trade date
Jan 1-Apr 13, 2022
Filing delay
111 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market sales total $211.5K. It was filed 111 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Oliviero James F IIICIK 0001434718Director, Officer (CEO, President and Director)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 1, 2022COMMON STOCKFTax withholdingDisposed−302,777$3.11−$941,636.473,305,433Direct
Jan 6, 2022COMMON STOCKFTax withholdingDisposed−53,024$2.77−$146,876.483,252,409Direct
Jan 24, 2022COMMON STOCKFTax withholdingDisposed−143,136$2.19−$313,467.843,109,273Direct
Jan 30, 2022COMMON STOCKFTax withholdingDisposed−31,972$2.46−$78,651.123,077,301Direct
Feb 24, 2022COMMON STOCKFTax withholdingDisposed−117,657$1.85−$217,665.452,959,644Direct
Apr 4, 2022COMMON STOCKSSaleDisposed−86,353$1.79F3−$154,571.872,873,291Direct
Apr 5, 2022COMMON STOCKSSaleDisposed−14,030$1.77F4−$24,833.12,859,261Direct
Apr 13, 2022COMMON STOCKSSaleDisposed−21,258$1.51F5−$32,099.582,838,003Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.77 to $1.81. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.75 to $1.78. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.51 to $1.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)